ImmunoGen begins Phase I cancer trial of IMGN853
The multi-centre, first-in-human trial, will enrol 64 patients to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and anticancer activity of the TAP compound. ImmunoGen vice president and chief medical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.